IO Biotech presented posters on preclinical studies at SITC Annual Meeting

Nov 13, 2017

Copenhagen, Denmark – November 13, 2017: IO Biotech announced that two posters summarizing recent preclinical findings in the company’s leading products, IO102 and IO103, were exhibited over the weekend at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, held in National Harbor, Maryland.

Other news

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

November 9, 2021
IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial

IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial

September 14, 2021
back to news overview